You are here

New Testosterone Treatment for Certain Forms of Hypogonadism

Majority of Trial Patients Achieved Normal Testoserone Levels

The FDA has approved testosterone undecanoate (Jatenzo, Clarus Therapeutics) an oral testosterone capsule for men with certain types of hypogonadism. These men have low testosterone levels caused by specific medical conditions, such as Klinefelter syndrome or tumors that have damaged the pituitary gland.

The oral method of administration is an important addition to the current options available for men with certain hypogonadal conditions who up until now have typically been treated with testosterone products that are applied to the skin or injected.

Testosterone undecanoate should not be used to treat men who have age-related hypogonadism, even if they have symptoms that seem to be related to low testosterone, as the benefits of the drug do not outweigh its risks for that use. The effects of testosterone undecanoate on raising blood pressure can increase the risks of heart attack, stroke, and cardiovascular death in this population.

The drug’s efficacy was demonstrated in a clinical trial with 166 men with hypogonadism. At the outset, participants received testosterone undecanoate 237 mg twice daily, then the dose was adjusted downward or upward to a maximum of 396 mg twice daily based on testosterone levels. Eighty-seven percent of patients treated with the drug achieved an average testosterone level within normal range, which was the primary endpoint.

Common side effects included headache, an increase in hematocrit, a decrease in high-density lipoprotein cholesterol, high blood pressure, and nausea. An increase in prostate specific antigen was also observed.

Testosterone undecanoate carries a boxed warning stating that the drug can cause a rise in blood pressure, increasing the risk for heart attack, stroke, and cardiovascular death. Before prescribing testosterone undecanoate, health care providers should consider the patient’s heart disease risks and ensure that blood pressure is adequately controlled.

Source: FDA, March 27, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions